Abstract. We recently showed that therapy with 2'-5'-oligo-adenylate (2-5A)-linked antisense against human telomerase RNA component (2-5A-anti-hTR) is a novel telomerase-targeting strategy against malignant gliomas. In this study, we investigated conventional chemotherapeutic agents and γ-irradiation (IR) to determine whether they could augment the efficacy of 2-5A-anti-hTR against these tumors in vitro and in vivo. Treatment with 2-5A-anti-hTR inhibited the viability of U373-MG and U87-MG malignant glioma cells in a dose-dependent manner; the antitumor effect resulted from induction of apoptosis. Also, telomerase-positive astrocytes with oncogenic Ras were more sensitive to 2-5A-anti-hTR than were those without oncogenic Ras. In addition, we sought to determine the combined effect of 2-5A-anti-hTR with N, N'-bis (2-chloroethyl)-N-nitrosourea (BCNU), cisplatin (CDDP), paclitaxel (PTX), temozolomide (TMZ), or IR. When we administered the combination treatments on the same day, PTX and IR showed a greater combined effect with 2-5A-anti-hTR on both tumor cell lines than did BCNU, CDDP and TMZ. However, all of the combination regimens were synergistic when we first treated tumor cells with 2-5A-anti-hTR for 24 h and then exposed them to the conventional treatments. Apoptosis-inducing agents (CDDP and PTX) but not autophagy-inducing therapies (TMZ and IR) enhanced the incidence of apoptosis caused by 2-5A-anti-hTR. Lastly, we observed a combinatorial effect of 2-5A-anti-hTR and TMZ in vivo in subcutaneous U87-MG tumors in nude mice. Interestingly, treatment with TMZ increased the incidence of apoptosis in subcutaneous tumor cells treated with 2-5A-anti-hTR. These results suggest that 2-5A-anti-hTR is preferable in combination with established cancer therapies.

Introduction

Malignant gliomas, including glioblastoma, are among the most devastating neoplasms (1). Although randomized trials have established the efficacy of radiotherapy for malignant gliomas, the addition of chemotherapy to radiotherapy did not result in a significant increase in survival rates (2). A recent clinical trial showed enhancement of survival in patients with newly diagnosed glioblastoma treated with the novel chemotherapeutic agent temozolomide (TMZ) together with radiation (3). However, the effectiveness of this combination was still modest. Therefore, exploration of new strategies for the treatment of malignant gliomas is needed.

Telomerase, an RNA-protein complex, adds hexameric repeats of 5'-TTAGGG-3' to the ends of telomeres to compensate for their progressive loss (4-6). Telomerase activity, which is generally undetectable in normal cells, is detectable in tumor cells in approximately 90% of all tumors (7,8). Telomerase activity is quite frequently detected in malignant gliomas (9). Specifically, telomerase activity is detected in 0 to 83% of World Health Organization Grade II gliomas. Furthermore, 25-100% of Grade III (anaplastic astrocytomas) and 53-100% of Grade IV (glioblastoma) malignant gliomas have telomerase activity. Additionally, researchers showed that patients with telomerase-negative glioblastomas had better survival durations than did those with telomerase-positive glioblastomas (10). In contrast, normal brain tissues do not have telomerase activity, whereas human embryonic neural precursor cells have detectable telomerase activity only at low levels (11). Therefore, telomerase is considered to be very attractive not only as a useful prognostic and diagnostic marker for malignant gliomas but also for targeted therapy for these tumors.

Based on the observations described above, we previously hypothesized that inhibition of telomerase activity could be a new strategy for the management of malignant gliomas (9). To pursue this hypothesis, we adopted the 2'-5'-oligo-adenylate (2-5A) system, which is a novel technology that exploits the body's natural antiviral defense by recruiting RNase L (12,13). RNase L is an endoribonuclease that functions in the interferon-regulated 2-5A system to degrade viral and cellular single-stranded RNAs. It is converted from
in 5% CO₂.

Cells were cultured in DMEM supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/ml penicillin and 100 μg/ml streptomycin. U87-MG and U373-MG human malignant glioma cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Human astrocytes expressing telomerase with or without oncogenic Ras (NHA/hTERT/Ras or NHA/hTERT) (23) were kindly provided by Dr Kenneth Aldape (M.D. Anderson Cancer Center). Cells were cultured in DMEM supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/ml penicillin (Invitrogen), and 2.5 μg/ml fungizone (Invitrogen) at 37°C in 5% CO₂.

Synthesis of 2-5A-anti-hTR. The antisense sequence was 5'-GCG CGG GGA GCA AAA GCA C-3'. The chimeric oligonucleotides were synthesized at Sigma-Genosys (Woodlands, TX) using a modification of spacer 19 instead of a butanediol linker to link 2-5A to the oligonucleotides.

**Materials and methods**

**Reagents.** CDDP and BCNU were purchased from Sigma Chemical Co. (St. Louis, MO). TMZ was purchased from the pharmacy at The University of Texas M.D. Anderson Cancer Center (Houston, TX). PTX was purchased from Hande Tech Co. Ltd., Tokyo, Japan. The recombinant adenovirus carrying p53 (Ad5CMV-p53) (21,22) was kindly provided by Dr. Y. Yamada (Tokyo Medical and Dental University, Tokyo, Japan). The anti-hTR was purchased form Genosys Biotechnologies, Inc., (The Woodlands, TX). The antisense oligonucleotides were synthesized at Sigma-Genosys (Woodlands, TX) using a modification of spacer 19 instead of a butanediol linker to link 2-5A to the oligonucleotides.

**Cell culture.** U87-MG and U373-MG human malignant glioma cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Human astrocytes expressing telomerase with or without oncogenic Ras (NHA/hTERT/Ras or NHA/hTERT) (23) were kindly provided by Dr Kenneth Aldape (M.D. Anderson Cancer Center). Cells were cultured in DMEM supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/ml penicillin (Invitrogen), and 2.5 μg/ml fungizone (Invitrogen) at 37°C in 5% CO₂.

**Synthesis of 2-5A-anti-hTR.** The antisense sequence was 5'-GCG CGG GGA GCA AAA GCA C-3'. The chimeric oligonucleotides were synthesized at Sigma-Genosys (Woodlands, TX) using a modification of spacer 19 instead of a butanediol linker to link 2-5A to the oligonucleotides.

**Cell viability assay.** The cytotoxic effect of 2-5A-anti-hTR on cultured cells was determined using a trypan blue dye exclusion. The cells were seeded at 2x10⁵ cells/well (0.1 ml) in 96-well plates and incubated overnight at 37°C. Oligonucleotides and Lipofectamine (Invitrogen) were then added to the wells every 24 h in the presence or absence of chemotherapeutic agents or IR. Cells treated with vehicle alone were considered to be 100% viable.

**Cell cycle assay.** For cell cycle analysis, tumor cells treated as described above were trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set (Roche Applied Science, Indianapolis, IN) as described previously (15,16). Samples were analyzed for DNA content using a FACScan flow cytometer and the CellQuest software program (Becton-Dickinson, San Jose, CA).

**Hoechst 33258 DNA staining.** The nuclei of cells were stained with Hoechst 33258 to detect chromatin condensation and nuclear fragmentation. Specifically, cells fixed with 4% paraformaldehyde were stained with Hoechst 33258 (0.5 μg/ml) for 15 min. Two hundred cells were counted and scored for the incidence of apoptotic chromatin changes under a fluorescence microscope.

**Detection of autophagy.** LC3, a mammalian homologue of Apg8p, is recruited to the autophagosome membrane during autophagy (24). Green fluorescent protein (GFP)-tagged LC3-expressing cells were used to demonstrate induction of autophagy. GFP-LC3 cells presented a diffuse distribution under control conditions, whereas a punctate pattern of GFP-LC3 expression was increased in number and fluorescence intensity by autophagy. Therefore, using a GFP-LC3 expression vector kindly provided by Dr Noboru Mizushima (Tokyo Medical and Dental University, Tokyo, Japan), the involvement of LC3 in tumor cells treated with the 2-5A-anti-hTR in the presence or absence of conventional cancer treatment was analyzed as described previously (25). Tumor cells were transfected with the GFP-LC3 expression vector using FuGENE 6 transfection reagent (Roche Applied Science). After overnight culture, cells were treated with 2-5A-anti-hTR with or without other treatments, fixed with 4% paraformaldehyde, and examined under a fluorescence microscope.

**Animal studies.** U87-MG cells (1x10⁶ cells in 20 μl of serum-free DMEM) were inoculated subcutaneously into the right flank of 5 to 10-week-old female nude mice (five mice in each treatment group). The resulting tumor growth was measured daily using calipers. Tumor volume was calculated as (L x W²)/2, in which L is the length in millimeters and W is the width in millimeters, as described previously (15,16). When the tumors reached a mean volume of 70-100 mm³, intratumoral injection of 2-5A-anti-hTR was initiated.
Specifically, 2-5A-anti-hTR (1 nmol/20 μl sterile water) with Lipofectamine (0.3 μl) was injected directly into the tumors every 24 h over 10 days (days 0-9). Also, TMZ (7.5 mg/kg) was administered into the peritoneal cavities of the mice over 9 days (days 1-9). The tumor volume was then measured every other day using calipers. Mice were euthanized by exposure to CO₂ on day 10. Their tumors were then removed, snap-frozen, and kept at -80˚C until use. Tumor specimens were sliced to a thickness of 10-20 μm using a cryostat, mounted on glass slides, fixed with 4% paraformaldehyde in PBS, and processed for immunohistochemical staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining (Oncor, Inc., Gaithersburg, MD, USA), according to the manufacturer's instructions. Animal studies were performed in the veterinary facilities at M.D. Anderson in accordance with institutional, state, and federal regulations and institutional and international ethics guidelines for the care and use of experimental animals.

Statistical analysis. Data were expressed as the mean ± standard deviation (SD). Statistical analysis was performed using Student’s t-test (two-tailed). The combined effect of 2-5A-anti-hTR and TMZ or IR was analyzed using a combination index (CI) isobologram with the Calcusyn software program (Biosoft, Ferguson, MO), as described previously (26).

Results and Discussion

Effect of 2-5A-anti-hTR on malignant glioma cells. To evaluate the effectiveness of 2-5A-anti-hTR against malignant glioma cells, we treated U87-MG and U373-MG cells with 2-5A-anti-hTR in the range between 0.1 and 0.5 μM in the presence of Lipofectamine (0.4 μl/100 μl) every 24 h for 3 days. We based these optimized treatment conditions on previous investigations (16,17). As shown in Fig. 1A, treatment with 2-5A-anti-hTR inhibited the viability of both U87-MG and U373-MG cells; 0.1 μM 2-5A-anti-hTR reduced the cell viability to 76% in U373-MG cells and 75% in U87-MG cells, whereas 0.5 μM 2-5A-anti-hTR reduced the cell viability to 29% in U373-MG cells and 22% in U87-MG cells. Based on these
data, we used 0.1 μM 2-5A-anti-hTR for combination treatment with chemotherapeutic agents and IR as described below.

**Induction of apoptosis in 2-5A-anti-hTR-treated malignant glioma cells.** To determine whether 2-5A-anti-hTR that we synthesized with a different linker induces apoptosis, we measured the percentage of subG1 population, which is characteristic of apoptosis. DNA flow cytometry revealed that the percentage of cells in the sub-G1 phase increased from 2.4 to 51.1% after treatment of U373-MG cells with 2-5A-anti-hTR (Fig. 1B). Furthermore, we stained the nuclei of treated U87-MG and U373-MG cells with Hoechst 33258 to determine whether apoptotic morphology is induced by 2-5A-anti-hTR. As shown in Fig. 1C, the majority of tumor cells treated with 2-5A-anti-hTR were apoptotic. These results indicated that 2-5A-anti-hTR induces apoptosis in malignant glioma cells.

**Effect of 2-5A-anti-hTR on genetically modified human astrocytes with telomerase activity and/or an oncogenic Ras gene.** In our previous studies, treatment with 2-5A-anti-hTR induced cell death in telomerase-positive malignant glioma cells (15,16). In contrast, telomerase-negative astrocytes were insensitive to this treatment, although all of the cells expressed hTR, which is a target of 2-5A-anti-hTR. These observations prompted us to hypothesize that the cytotoxicity of 2-5A-anti-hTR depends on tumorigenicity as well as telomerase activity. To test our hypothesis, we compared the effect of 2-5A-anti-hTR on tumorigenic astrocytes expressing telomerase and oncogenic Ras (NHA/hTERT/Ras) with that on non-tumorigenic astrocytes expressing telomerase alone (NHA/hTERT). These astrocytes were genetically established to demonstrate the development of malignant gliomas (23). To immortalize human astrocytes, hTERT and human papillomavirus E6/E7 (to inactivate both p53 and pRb) genes were introduced by retroviral transfer. Although NHA/hTERT cells that escaped from senescence can grow indefinitely in culture, anchorage-independent growth of these cells as transformed cells in soft agar and as tumors in animals was undetectable. After introduction of an oncogenic Ras gene (H-Ras V12), NHA/hTERT/Ras cells acquired tumorigenicity. As shown in Fig. 1D, NHA/hTERT/Ras cells were more sensitive to 2-5A-anti-hTR than NHA/hTERT were (P<0.05). These results indicated that the cytotoxic effect of 2-5A-anti-hTR may depend not only on telomerase activity but also on tumorigenicity, suggesting that 2-5A-anti-hTR initiates the tumor-specific cell death pathway.

**Effect of chemotherapeutic agents and IR on the viability of malignant glioma cells.** To determine the effect of CDDP, TMZ, PTX, BCNU and IR on the viability of U373-MG and U87-MG cells, we treated these cells with them at various concentrations and doses over 3 days. As shown in Fig. 2, both cell lines showed similar dose-dependent sensitivity to these treatments. Treatment with 1.5 μM CDDP reduced the cell viability to 81 and 70% in U373-MG and U87-MG cells, respectively. Treatment with TMZ at 1 μM reduced the cell viability to 83 and 76% in U373-MG and U87-MG cells, respectively. Administration of 2 Gy of IR reduced the cell viability to 83% in both U373-MG and U87-MG cells. Exposure to 1 nM PTX reduced the cell viability to 79 and 82% in U373-MG and U87-MG cells, respectively. Finally, treatment with 1 μM BCNU reduced the cell viability to 86 and 85% in U373-MG and U87-MG cells, respectively. We used these concentrations and doses (approximately the 80% inhibitory effects) for combination treatments with 2-5A-anti-hTR.

**Combined effect of 2-5A-anti-hTR with chemotherapeutic agents and IR on the viability of malignant glioma cells.**
We also investigated 2-5A-anti-hTR to determine whether it enhances the effects of chemotherapy and radiotherapy on human malignant glioma. First, we treated U373-MG and U87-MG cells with 2-5A-anti-hTR and BCNU, CDDP, PTX, TMZ, or IR on the same day. As shown in Fig. 3A, CDDP, PTX, and IR exhibited a better combined effect with 2-5A-anti-hTR on U373-MG cells than BCNU and TMZ did (P<0.05, respectively). In comparison, PTX and IR enhanced the effect of 2-5A-anti-hTR on U87-MG cells more than BCNU, CDDP and TMZ did. Namely, in the concurrent treatment regimens, PTX and IR showed a better combinatorial effect with 2-5A-anti-hTR than the other three conventional treatments did on both cell lines. Second, we changed the treatment sequence to optimize the combination regimens. After we first treated tumor cells with 2-5A-anti-hTR for 24 h, we exposed them to conventional treatments. BCNU, CDDP, PTX, TMZ, and IR all exhibited a strong combinatorial effect with 2-5A-anti-hTR on both U373-MG and U87-MG cells (P<0.05) (Fig. 3B). Previous investigations demonstrated that some cancer treatments inhibit telomerase activity (27-30). Because the antitumor activity of 2-5A-anti-hTR depends on telomerase activity, treating tumor cells with 2-5A-anti-hTR until the telomerase activity in them is remarkably inhibited by conventional treatments may be beneficial. As expected, when we administered 2-5A-anti-hTR 1 day after administering the conventional therapies, the combined effects were largely diminished, supporting our speculation above.

Next, we evaluated these combined effects to determine whether they were synergistic or additive, especially for TMZ and IR, because these treatments are considered promising adjuvant therapies after surgery (3). We calculated the CI value and plotted the isobologram at the 50% inhibitory concentrations. As shown in Fig. 3C, all of the plots except one (1 μM TMZ with 2-5A-anti-hTR in U373-MG) were synergistic in U373-MG and U87-MG for the combination of 2-5A-anti-hTR and TMZ or IR. These results suggested that 2-5A-anti-hTR synergistically sensitized both U373-MG and U87-MG to TMZ and IR.

Figure 3. Combined effect of 2-5A-anti-hTR with chemotherapeutic agents and IR on the viability of malignant glioma cells. (A) Concurrent combination treatment. Cells were treated with 0.1 μM 2-5A-anti-hTR every 24 h over 3 days starting on day 0 with or without BCNU (1 μM), CDDP (1.5 μM), PTX (1 nM), TMZ (1 μM), or IR (2 Gy) on day 0 for 24 h. Tumor cells were then trypsinized and the viable cells were counted. The results shown are the means ± SD. *P<0.05. (B) Sequence-changed combination treatment. One day after treatment with 0.1 μM 2-5A-anti-hTR, tumor cells were treated with BCNU (1 μM), CDDP (1.5 μM), PTX (1 nM), TMZ (1 μM), or IR (2 Gy). Next, treatment with 2-5A-anti-hTR was repeated on days 1, 2 and 3. WST-1 assay was then performed. The results shown are the means ± SD. *P<0.05. (C) IC50 isobolograms of the combination treatments. U373-MG and U87-MG cells were treated with 0.1 μM 2-5A-anti-hTR every 24 h over 3 days starting on day 0 with TMZ (0-1,000 μM) or IR (0-20 Gy) on day 1 for 24 h. The viable cells were then counted. In the isobolograms, the plots on the diagonal lines indicate that this combination was additive. The plots on the left under the line indicate that it was synergistic, and the plots on the right above the line indicate that it was antagonistic.
Detection of apoptosis and autophagy in malignant glioma cells treated with 2-5A-anti-hTR in the presence or absence of PTX, TMZ, or IR.

Previously, malignant glioma cells underwent apoptosis after treatment with 2-5A-anti-hTR (Fig. 1B and C) and PTX (31), whereas cells underwent non-apoptotic autophagy after treatment with TMZ or IR (32,33). Therefore, we sought to determine whether the combination treatments affected the induction of apoptosis caused by 2-5A-anti-hTR or induced autophagy. As shown in Fig. 4A, 6 and 3% of untreated U373-MG and U87-MG cells, respectively, underwent apoptosis. Treatment with 2-5A-anti-hTR at 0.1 μM for 3 days induced apoptosis in 16 and 13% of U373-MG and U87-MG cells, respectively. Also, treatment with PTX at 1 nM induced apoptosis in 10 and 7% of U373-MG and U87-MG cells, respectively. In addition, treatment with IR at 2 Gy, which induced apoptosis in 9 and 8% of U373-MG and U87-MG cells, respectively, did not affect the incidence of apoptosis caused by 2-5A-anti-hTR. In combination with PTX, TMZ, or IR (32,33). Therefore, we sought to determine whether the combination treatments affected the induction of apoptosis caused by 2-5A-anti-hTR or induced autophagy.

Recent studies have discovered non-apoptotic autophagic cell death in cancer therapy (31,34). Therefore, we sought to determine whether autophagy is induced in malignant glioma cells by 2-5A-anti-hTR with or without treatment with PTX, TMZ, or IR. As shown in Fig. 4B, U373-MG cells not treated with 2-5A-anti-hTR showed diffuse distribution of GFP, indicating that they were not autophagic. When we treated these cells with 2-5A-anti-hTR, very few cells showed a punctate pattern of GFP, indicating that they were autophagic cells. We then quantified the percentage of autophagic U373-MG and U87-MG cells. As shown in Fig. 4C, <10% of U373-MG and U87-MG cells treated with 2-5A-anti-hTR, PTX, IR, or combination therapy did not increase the percentage of autophagic cells compared with treatment with 2-5A-anti-hTR.
IR had GFP-LC3 dots. Although IR at 2 Gy significantly induced autophagy in U87-MG cells (9%; P<0.05 when compared with control cells), the addition of 2-5A-anti-hTR did not affect induction of autophagy. Treatment with TMZ at 1 μM also induced autophagy in U87-MG (16%) and U373-MG (9%) cells. However, treatment with the combination of TMZ and 2-5A-anti-hTR did not significantly increase the percentage of autophagic cells. These results indicated that 2-5A-anti-hTR induces apoptosis but not autophagy in malignant glioma cells.

Combinatorial effect of 2-5A-anti-hTR and TMZ in vivo. Because TMZ and IR showed a similar combined effect with 2-5A-anti-hTR on malignant glioma cells, we decided to explore the in vivo antitumor effect of 2-5A-anti-hTR in the presence or absence of TMZ. When subcutaneous xenografts derived from U87-MG cells in nude mice reached a mean volume of 70-100 mm³ (defined as day 0), we injected 2-5A-anti-hTR (1 nmol/20 μl sterile distilled water) with Lipofectamine (0.3 μl) directly into the tumors daily from day 0 to day 9. Also, we administered TMZ (7.5 mg/kg) into the peritoneal cavities of the mice daily from day 1 to day 9. We measured the size of the resulting tumors every other day until day 10. As shown in Fig. 5A, mice treated with TMZ had tumors about 74% smaller than those in the control mice on day 10 (mean volume = 1427.0±100.0 mm³ in control mice and 379.3±26.6 mm³ in TMZ-treated mice; P<0.01). Also, mice given 2-5A-anti-hTR had tumors about 50% smaller than those in the control mice on day 10 (mean volume = 711.7±9.9 mm³ in 2-5A-anti-hTR-treated mice; P<0.01). Finally, mice given the combination of TMZ and 2-5A-anti-hTR had tumors about 88% smaller than those in the control mice on day 10 (mean volume = 172.7±12.1 mm³ in TMZ and 2-5A-anti-hTR-treated mice; P=0.021, TMZ vs. 2-5A-anti-hTR plus TMZ; P=0.035, 2-5A-anti-hTR vs. 2-5A-anti-hTR plus TMZ) (Fig. 5A).

We removed the subcutaneous tumors from the mice on day 10 and processed them for TUNEL staining. As shown in Fig. 5B, we detected TUNEL-positive cells mainly among tumor cells treated with 2-5A-anti-hTR alone or combined with TMZ. Our quantification of apoptosis incidence revealed that the apoptosis rate was 5% in 2-5A-anti-hTR-treated mice.
tumors, but <2% in control- and TMZ-treated tumors (Fig. 5C). The apoptosis rate was 9% in the TMZ- and 2-5A-anti-hTR-treated tumors (P=0.014, compared with 2-5A-anti-hTR; P=0.006, compared with TMZ). Although treatment with TMZ alone did not significantly induce apoptosis, it may have affected some factors that stimulate the apoptotic pathway directly or indirectly when combined with 2-5A-anti-hTR. Further study is necessary to identify the molecular mechanisms underlying the discrepancy in in vitro and in vivo settings. These results indicated that treatment with the combination of TMZ and 2-5A-anti-hTR effectively inhibits the growth of malignant glioma cells in vivo through apoptosis.

In this study, we showed that treatment with 2-5A-anti-hTR induced apoptosis in malignant glioma cells within 3 days after the initiation of treatment. Treatment with 2-5A-anti-hTR in the presence of BCNU, CDDP and TMZ better enhanced the cell-killing effect when done sequentially rather than concurrently; treatment with 2-5A-anti-hTR in the presence of PTX and IR enhanced this effect at similar levels both concurrently and sequentially. The enhanced cell-killing effect resulted from apoptosis. In comparison, 2-5A-anti-hTR did not impaire the autophagy induced by treatment with TMZ or IR. TMZ and IR, which are considered promising adjuvant therapies for malignant glioma, showed a synergistic combined effect with 2-5A-anti-hTR. In our animal xenograft model, TMZ enhanced the anti-tumor effect of 2-5A-anti-hTR via induction of apoptosis.

Accumulating evidence has raised considerable interest in telomerase inhibition as a potential cancer therapy (9). Recently, studies identified six subunits that make up the human telomerase complex: hTR (35), telomerase-associated protein 1 (TEP1) (36,37), hTERT (38,39), heat shock protein 90 (HSP90) (40), the molecular chaperone p23 (40), and dyskerin (41). hTERT functions as a template for telomere elongation by telomerase. TEP1, which is homologous to the Tetrahymena telomerase component gene p80, is associated with RNA and protein binding. hTERT contains reverse transcriptase motifs and functions as the catalytic subunit of telomerase. HSP90 and p23 can bind to hTERT and contribute to telomerase activity. Dyskerin, which is the pseudouridine synthase component of the box H + ACA snRNAs, also interacts with hTR. Three major subunits (hTR, TEP1, and hTERT) correlate with telomerase activity, whereas the association between telomerase activity and expression of HSP90, p23 and dyskerin remains unclear. Strategies for inhibition of telomerase activity have focused on antisense oligonucleotides against hTERT and hTERT, inhibitors of reverse transcriptases, and small molecules able to interact with and stabilize four-stranded (G-quadruplex) structures formed by telomeric DNA (28,35,42-45).

These investigations show that inhibition of telomerase activity suppresses the proliferation of cancer cells and the growth of tumor xenografts in animals, indicating that telomerase is a promising therapeutic target for cancer. However, one of the major limitations of targeting telomerase in tumors is that telomeric DNA must shorten considerably before tumor cells undergo cell death or senescence. In other words, there is a lag between the time telomerase is inhibited and the time telomeres of the cancer cells shorten sufficiently to exhibit a significant effect on cellular proliferation. Therefore, the lag must be shortened by modifying the telomerase inhibition approach or developing a telomerase inhibition system that induces cell death rapidly. As we and others recently showed, 2-5A-anti-hTR induces a cell-killing effect or apoptosis regardless of the telomere length, indicating the attractiveness of 2-5A-anti-hTR in cancer therapy.

Acknowledgments

We thank Dr Noboru Mizushima for the GFP-LC3 vector. We also thank E. Faith Hollingsworth for technical support and Donald R. Norwood for editing the manuscript. This study was supported in part by USPHS Grants CA088936 and CA108558 from the National Cancer Institute, a start-up fund from M.D. Anderson (to S.K.), a generous donation from the Anthony D. Bullock III Foundation (to Y.K., S.K.), and the Cancer Center Support (Core) Grant Shared Resources.

References


